ChemComm

Accepted Manuscript



ROYAL SOCIETY OF CHEMISTRY

www.rsc.org/chemcomm

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

COMMUNICATION

Palladium-catalyzed cyclization of benzamides with arynes: application to the synthesis of Phenaglydon and *N*-Methylcrinasiadine

Sandeep Pimparkar and Masilamani Jeganmohan*

Received (in XXX, XXX) Xth XXXXXXXXX 20XX, Accepted Xth XXXXXXXXX 20XX

DOI: 10.1039/b000000x

***N*-Methyl or methoxy benzamides reacted with benzynes in the presence of $Pd(OAc)_2$, organic acid and $K_2S_2O_8$ in CH_3CN yielding tricyclic phenanthridinone derivatives in good yields.**

Phenanthridinones are key core units found in various natural products and biologically active molecules.[1] This molecule is used as a potential PARP-1 inhibitor anticancer drug as well as neurotrophin activity enhancers for the treatment of nerve diseases.[2] Traditionally, phenanthridinones are synthesized by cyclization of nitrocarbonyl-biphenyls, Beckmann/Schimdt rearrangement of fluorenones and photoinduced rearrangement of 2-halobenzamides.[3] However, in these reactions, the preparation of key starting materials need more steps and the overall yields observed were lower. Subsequently, phenanthridinones are prepared by a palladium-catalyzed homo coupling of *ortho*-halo benzamides and coupling of aromatic halides with *ortho*-halo benzamides.[4] Very recently, Larock's group reported the synthesis of phenanthridinones via a palladium-catalyzed cyclization of *ortho*-halo *N*-substituted benzamides with benzynes (eq 1).[5] But, a preactivated carbon-halogen partner on the aromatic moiety is required for the reaction. Apart from these reactions, phenanthridinones are prepared by a metal-catalyzed *ortho* arylation of benzamides with iodobenzenes or aromatic boronic acids or electron-rich aromatics followed by intramolecular C-N bond formation.[6]



Transition metal-catalyzed cyclization of heteroatom substituted aromatics with carbon-carbon π-components via chelation-assisted C-H bond activation is a practical method to synthesize heterocyclic molecules in one pot.[7] By using nitrogen containing chelating groups such as amide, oxime and imine substituted aromatics or alkenes, various nitrogen-containing mono- and bicyclic heterocycles are prepared through the consecutive C-C and C-N bond formation.[7] In the cyclization reaction, alkynes, alkenes and allenes are extensively used as carbon-carbon π-components (eq 1). However, benzyne as a π-component has not been well explored in the literature. In fact, there are several challenges to utilize benzyne as a π-component in the reaction due to its high reactivity. It is very important to note that in the cyclization of substituted aromatics with benzynes, a tricyclic ring system can be constructed in one pot.

Table 1 Cyclization of benzamide **1a** with benzyne precursor **2a**[a]



Entry	Catalyst/Additive	Oxidant	**3a**/**4a** Yield (%)[b]
1	$[RuCl_2(p\text{-cymene})]_2/AgSbF_6$[c]	$Cu(OAc)_2$	30/0
2	$Pd(OAc)_2$/AcOH	-	-
3	$Pd(OAc)_2$/TFA	-	-
4	$Pd(OAc)_2$/pivalic acid	-	10/35
5	$Pd(OAc)_2$/Adm-1-COOH[d]	-	0/45
6	$Pd(OAc)_2$/Adm-1-COOH[d]	Ag_2O	0/33
7	$Pd(OAc)_2$/Adm-1-COOH[d]	Ag_2CO_3	0/27
8	$Pd(OAc)_2$/Adm-1-COOH[d]	AgOAc	0/45
9	$Pd(OAc)_2$/Adm-1-COOH[d]	$K_2S_2O_8$	0/74
10	$Pd(OAc)_2$/Adm-1-COOH[d]	$PhI(OAc)_2$	-
11	$Pd(OAc)_2$/Adm-1-COOH[d]	$(NH_4)_2S_2O_8$	-

[a]Reactions conditions: **1a** with **2a** (1.5 equiv) in the presence of cat (5.0 mol %), additive (10.0 equiv) and oxidant (2.0 equiv) in CH_3CN at 100 °C for 12 h. [b]GC yield. [c]$AgSbF_6$ (20 mol %) was used. [d]Adm-1-COOH (30 mol %) was used.

We have focused on utilization of a highly reactive benzyne as a π-component in the cyclization reaction. Initially, we have tried the cyclization of *N*-methoxy 4-methoxy benzamide (**1a**) with *o*-(trimethylsilyl)aryl triflate (**2a**) in the presence of $[\{RuCl_2(p\text{-cymene})\}_2]$, $AgSbF_6$ and $Cu(OAc)_2$ in CH_3CN at 100 °C for 12 h (Table 1, entry 1). CsF in CH_3CN was used to generate benzyne from benzyne precursor **2a**.[8] In the reaction, only *N*-arylated benzamide **3a** was observed in 30% yield and the expected cyclization product **4a** was not observed. Next, the cyclization reaction of **1a** with **2a** was examined in the presence of $Pd(OAc)_2$ (5 mol %) and acetic acid or CF_3COOH (10.0 equiv) in CH_3CN (entries 2 and 3). In the reaction, no *N*-arylation product **3a** or cyclization product **4a** was observed. It seems AcOH or CF_3COOH might quench the CsF base. Then, acetic acid was replaced by the sterically hindered pivalic acid (entry 4). Interestingly, in the reaction, the expected cyclization product **4a** was observed in 35% yield and competitive product **3a** was also observed in 10% yield. To avoid product **3a**, the reaction was tested with a catalytic amount of 1-adamantanecarboxylic acid (Adm-1-COOH) (30 mol %) (entry 5). Surprisingly, in the reaction, product **4a** was observed in 45% yield and no *N*-arylated product **3a** was observed. To increase the yield of

product **4a**, the reaction was examined with oxidants (1.0 equiv) (entries 6-11). Interestingly, using $K_2S_2O_8$, product **4a** was observed in 74% GC yield and 66% isolated yield (entry 9). Remaining oxidants were partially effective or totally ineffective, yielding **4a** in 0-45% yields (entries 6-11).



Scheme 1 Scope of the *N*-methoxy benzamides **1**

The scope of the catalytic reaction was tested with substituted *N*-methoxy benzamides **1b-i** (Scheme 1). 2-Methoxy (**1b**), 4-methyl (**1c**) and *N*-methoxy benzamides (**1d**) underwent cyclization with **2a**, yielding phenanthridinones **4b-d** in 55%, 62% and 61% yields, respectively. Next, the cyclization reaction was tested with unsymmetrical benzamides. *N*-Methoxy 3,4-dimethoxy benzamide (**1e**) and *meta* methoxy benzamide **1f** afforded phenanthridinones **4e** and **4f** in 61% and 58% yields, respectively, in which the *ortho* C-H bond activation takes place selectively at a sterically less hindered side. Whereas, benzamide **1g** provided mixtures of regioselective cyclization products **4g** and **4g'** in 60% combined yield in a 1.5:1 ratio. Further, the cyclization reaction was tested with 4-bromo and 4-chloro benzamides **1h** and **1i**. However, only *N*-arylated benzamides **3h** and **3i** were observed in 47% and 51% yields, respectively and the expected cyclization products **4** were not observed. Similarly, 4-trifluoromethyl, 4-cyano and 4-nitrobenzamides were also not compatible for the reaction. This result clearly reveals that electron-donating substituents on the aromatic moiety of benzamides favor the *ortho* C-H bond activation/cyclization reaction. But, halogen and electron deficient aromatic benzamides favor only competitive nucleophilic addition of free N-H moiety of benzamide with benzyne. Surprisingly, the palladacycle of 4-chloro benzamide **5a** reacted with benzyne precursor **2a**, yielding cyclization product **4h** in 45% yield. This result clearly says that the *ortho* C-H bond activation process is very slow in the electron deficient benzamides, and the competitive nucleophilic addition is very fast. Although, at present, the catalytic reaction was compatible with only electron-rich benzamides, it has been shown that a highly reactive benzyne can be used as a π-component for the cyclization reaction.



Scheme 2 Scope of the benzyne precursors **2b-e**

The cyclization reaction was also examined with benzyne precursors **2b-e** (Scheme 2). Treatment of benzamide **1a** with benzyne precursors **2b** and **2c** gave phenanthridinones **4i** and **4j** in 61% and 55% yields, respectively. Interestingly, synthetically useful benzyne precursors **2d** and **2e** reacted with **1e**, giving products **4l** and **4m** in 70% and 63% yields, respectively.



Scheme 3 Scope of the *N*-methyl benzamides **6a-d**

The catalytic reaction was further tested with other *N*-methyl benzamides (Scheme 3). *N*-Methyl benzamide (**6a**) underwent cyclization with **2a**, providing *N*-methyl phenanthridinone **7a** in 49% yield, in which *ortho* C-H bond activation takes place selectively at the sterically less hindered side. Further, *N*-methyl 4-methoxy benzamide (**6b**) and *N*-methyl benzamide (**6c**) reacted with **2a** or **2c** affording cyclization products **7b-d** in 45%, 43% and 38% yields, respectively. Treatment of *N*-methyl benzamide **6d** with **1a** gave natural product *N*-methylcrinasiadine[10b] (**7e**) in 30% yield and other regioisomer **7e'** in 25% yield, respectively. It is important to point out that natural product *N*-methylcrinasiadine (**7e**) shows several biological activities.[1]



Later, OMe group on the cyclic amides of **4c** and **4d** were cleaved into the natural product phenaglydon[9a-b] **8a** in 69% yield and 6(5*H*)-phenanthridinone **8b** in 67% yield under the

photochemical irradiation conditions[7a-b] (eq 2). Later, compound **8b** underwent nitration at C-5 position of phenanthridinone in the presence of HNO_3/H_2SO_4, providing 5-nitro phenanthridinone **9** in 75% yield. It is important to note that compound **9** is a key precursor for the preparation of anti-cancer drug PJ34.[9c]



Scheme 4 Proposed mechanism

A possible reaction mechanism is proposed in Scheme 4 to account for the present cyclization reaction. Coordination of the amide nitrogen of benzamide **1** to the palladium species followed by *ortho*-metalation provides a five-membered palladacycle intermediate **5**. Coordinative insertion of benzyne **10** into the intermediate **5** yields a seven-membered palladacycle intermediate **11**. Subsequent C-N bond formation and reductive elimination affords product **4** and regenerates the active palladium species in the presence of RCOOH and $K_2S_2O_8$.



Scheme 5 Mechanistic investigation

Apart from the above proposed mechanism, other possible pathways such as *ortho*-arylation of benzamide with benzyne yielding product **12** followed by intramolecular C-N bond formation or N-H arylation of benzamide with benzyne providing compound **3** followed by intramolecular dehydrogenative aryl-aryl coupling are also possible.[7] To support the proposed mechanism in Scheme 4, the following reactions were done (Scheme 5). *ortho*-Arylated benzamide **12** was prepared separately and treated with $Pd(OAc)_2$, CsF and $K_2S_2O_8$ in CH_3CN at 100 °C for 12 h. In the reaction, no cyclization product **4a** was observed. Subsequently, *N*-arylated benzamide **3a** was treated with $Pd(OAc)_2$ and $K_2S_2O_8$ under similar reaction conditions. However, no cyclization product **4a** was observed. Further, a five-membered palladacycle intermediate **5b** was prepared separately and treated with benzyne precursor **2a** in the presence of CsF in CH_3CN at 100 °C for 12 h. As expected, the cyclization product **4f** was observed in 75% yield. These results clearly revealed that the present reaction proceeds via coordinative insertion pathway. To support the hypothesis that benzyne is involved in the cyclization reaction, the reaction of benzamide **1a** with unsymmetrical benzyne precursor **2g** was performed. In the reaction, a mixture of regioisomeric compounds **4n** and **4n'** were observed in 53% combined yield in a 2:1 ratio. The lack of regioselectivity of the reaction is consistent with insertion of unsymmetrical benzyne into a Pd-carbon bond in intermediate **5**.

In conclusion, we have demonstrated a palladium-catalyzed oxidative cyclization of *N*-substituted benzamides with benzynes providing phenanthridinones with diverse substituents.

We thank the DST (SR/S1/OC-26/2011), India for the support of this research. S. P. thanks the BRNS for a fellowship.

Notes and references

[a]*Department of Chemistry, Indian Institute of Science Education and Research, Pune 411021, India; E-mail: mjeganmohan@iiserpune.ac.in*

† Electronic Supplementary Information (ESI) available: Detailed experimental procedures and spectroscopic data. See DOI: 10.1039/b000000x/

1 (*a*) F. Aprile-Garcia, M. Antunica-Noguerol, M. L. Budzinski, A. C. Liberman and E. Arzt, *Endocrine Connections*, 2014, **3**, 1; (*b*) S. E. Nasrabady, A. Kuzhandaivel, M. Mladinic and A. Nistri, *Cell Mol. Neurobiol*, 2011, **31**, 503; (*c*) Z. Jin, *Nat. Prod. Rep*., 2009, **26**, 363; (*d*) J. P. Michael, *Nat. Prod. Rep.*, 1995, **12**, 465.

2 (*a*) T. Harayama, H. Akamatsu, K. Okamura, T. Miyagoe, T. Akiyama, H. Abe and Y. Takeuchi, *J. Chem. Soc. Perkin Trans. 1* 2001, 523; (*b*) T. Harayama, Y. Akiyama, K. Nakano, H. Shibaike, A. Akamatsu, H. Hori, H. Abe, and Y. Takeuchi, *Synthesis* 2002, 237. (*c*) V. Holl, D. Coelho, D. Weltin, P. Dufour and P. Bischoff, *Anticancer Res.* 2000, **20**, 3233; (*d*) S. Patil, S. Kamath, T. Sanchez, N. Neamati, R. F. Schinazi and J. K. Buolamwini, *Bioorg. Med. Chem*. 2007, **15**, 1212.

3 (*a*) A. K. Mohanakrishnan and P. C. Srinivasan, *J. Org. Chem.* 1995, **60**, 1939; (*b*) R. Kleppinger, C. P. Lillya and C. Yang, *J. Am. Chem. Soc.* 1997, **119**, 4097; (*c*) M. G. Banwell, D. W. Lupton, X. Ma, J. Renner and M. O. Sydnes, *Org. Lett.* 2004, **6**, 2741; (*d*) R. Kleppinger, C. P. Lillya and C. Yang, *J. Am. Chem. Soc.* 1997, **119**, 4097; (*e*) L. M. N. Meseroll, J. R. McKee and M. Zanger, *Synth. Commun.* 2011, **41**, 2557; (*f*) A. Padwa, M. Dimitroff, A. G. Waterson and T. Wu, *J. Org. Chem.* 1998, **63**, 3986; (*g*) H. Suzuki, T. Enya and Y. Hisamatsu, *Synthesis* 1997, 1273.

4 (*a*) T. Furuta, Y. Kitamura, A. Hashimoto, S. Fujii, K. Tanaka and T. Kan, *Org. Lett*. 2007, **9**, 183; (*b*) P. H. Bernardo, W. Fitriyanto and C. L. L. Chai, *Synlett* 2007, 1935; (*c*) R. Ferraccioli, D. Carenzi, O. Rombola and M. Catellani, *Org. Lett.* 2004, **6**, 4759; (*d*) V. Rajeshkumar, T.-H. Lee and S.-C. Chuang, *Org. Lett*. 2013, **15**, 1468.

5 C. Lu, A. V. Dubrovskiy and R. C. Larock, *J. Org. Chem.* 2012, **77**, 8648, references therein.

6 (*a*) P. Thansandote and M. Lautens, *Chem. Eur. J.* 2009, **15**, 5874; (b) T. Satoh and M. Miura, *Chem. Eur. J.* 2010, **16**, 11212; (*c*) G. Song, F. Wang and X. Li, *Chem. Soc. Rev*. 2012, **41**, 3651; (*d*) H. Wang and F. Glorius. *Angew. Chem. Int. Ed.* 2012, **51**, 7318; (*f*) P. B. Arokiam, C. Bruneau and P. H. Dixneuf, *Chem. Rev*. 2012, **112**, 5879; (*g*) L. Ackermann, *Acc. Chem. Res*. 2014, **47**, 281; (*h*) T. W. Lyons and M. S. Sanford, *Chem. Rev*. 2010, **110**, 1147.

7 (*a*) T.-T. Yuan, D.-D. Li and G.-W. Wang *Angew. Chem. Int. Ed.* 2011, **50**, 1380; (*b*) J. Karthikeyan and C.-H. Cheng, *Angew. Chem. Int. Ed.* 2011, **50**, 9880; (*c*) J. Karthikeyan, R. Haridhadharan and C.-H. Cheng, *Angew. Chem, Int. Ed.* 2012, **51**, 12343; (*d*) N. Senthilkumar, K. Parthasarathy, G. Parthasarathy and C.-H. Cheng, *Chem. Asian J.* 2013, **8**, 2175. (*e*) C. S. Yeung, X. Zhao, N. Borduas and V. M. Dong, *Chem. Sci.* 2010, **1**, 331.

8 Y. Himeshima, T. Sonoda, H. Kobayashi, *Chem. Lett.* 1983, 1211.

9 (*a*) G. Wurz, O. Hofer and H. Greger *Nat. Prod. Lett.* 1993, **3**, 177; (*b*) R. Suau, A. I. Gomez and R. Rico, *Phytochemistry* 1990, **29**, 1710; (*c*) Z. Tu, W. Chu, J. Zhang, C. S. Dence, M. J. Wench and R. H. Mach, *Nucl. Med. Biol.* 2005, **32**, 437.